Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Respiratory indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Asthma-COPD overlap and diagnostic uncertainty

Respiratory · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

During acute deterioration, treat physiological severity and likely exacerbation triggers before perfecting a chronic label. Severe breathlessness, hypoxaemia, altered consciousness, silent chest, exhaustion, chest pain, haemoptysis or acute hypercapnic acidosis needs immediate ABCDE care, controlled oxygen where hypercapnic risk exists, senior assessment and the relevant acute asthma, COPD or alternative emergency pathway.

Overview

Resolve chronic airway diagnostic uncertainty using objective evidence and treat demonstrated asthma and COPD traits without allowing an overlap label to replace careful clinical reasoning.

The same patient may have childhood or adult-onset asthma, later acquire smoking-related fixed obstruction, and present in older age with symptoms contributed by both. Another patient may have COPD with eosinophilic inflammation but no convincing asthma history. These are not identical situations. The useful question is which traits are securely present and which treatment prevents harm, not whether a fashionable combined acronym can be applied.

A structured assessment separates history, physiology, inflammation and competing disease. Asthma evidence includes episodic variability, atopy, earlier onset, marked or repeated objective variability and documented response to anti-inflammatory treatment. COPD evidence includes chronic progressive exertional dyspnoea or cough, tobacco or occupational exposure, and persistent post-bronchodilator obstruction. Neither list is absolute; NICE recommends using additional findings when uncertainty remains or both conditions are present.

Aetiology

01

Asthma with persistent obstruction

Long-standing airway inflammation and remodelling can leave an adult with asthma features but incompletely reversible post-bronchodilator obstruction.

02

COPD with asthma traits

A person with smoking or occupational injury and persistent obstruction may also have variable symptoms, atopy, eosinophilic inflammation or earlier asthma.

03

Dual exposure and susceptibility

Early-life airway vulnerability combined with later tobacco, pollution or workplace exposure can produce mixed clinical and physiological features.

04

Misclassification

Poor-quality spirometry, treatment effects, obesity, bronchiectasis or an incomplete history may create apparent overlap when a different or single diagnosis better explains disease.

Pathophysiology

  1. 1
    Variable inflammatory activity

    Type 2 or other asthma-associated inflammation drives episodic bronchoconstriction and symptoms within an airway already affected by chronic injury.

  2. 2
    Persistent small-airway narrowing

    Remodelling, mucus and exposure-related bronchiolitis reduce expiratory calibre and prevent airflow from returning fully to predicted levels.

  3. 3
    Loss of recoil

    Where emphysema is present, alveolar destruction removes airway tethering and adds gas trapping to bronchial narrowing.

  4. 4
    Heterogeneous expression

    The relative contributions of asthma traits, emphysema and chronic bronchitis vary over time, so one overlap label does not specify mechanism or treatment need.

Clinical features and red flags

Asthma-predominant pattern

Variable wheeze, cough or chest tightness, night or trigger pattern, atopy, earlier onset and repeated objective variability support asthma even when current post-bronchodilator obstruction remains fixed.

COPD-predominant pattern

Persistent progressive exertional breathlessness, chronic cough or sputum, substantial smoke or occupational exposure and stable post-bronchodilator obstruction support COPD, particularly with emphysema or reduced gas transfer.

Both conditions plausible

A well-evidenced asthma history precedes later persistent obstruction after harmful exposure, or repeated variability coexists with structural COPD. Document the evidence for each instead of using overlap as the only diagnosis.

High-risk asthma signalRed flag

Previous life-threatening attack, repeated systemic corticosteroid, night waking, marked variability or escalating reliever use warrants an asthma-safe ICS-containing regimen while diagnostic refinement continues.

Investigations

  1. 01
    Quality-assured pre- and post-bronchodilator spirometryFirst step
    Why
    Determine obstruction, persistence and immediate bronchodilator response.
    Interpretation and limitations
    Use age-appropriate reference limits and an acceptable, repeatable trace. Persistent post-bronchodilator obstruction supports COPD in context but also occurs in remodelled asthma; reversibility can occur in both and is not a binary separator.
  2. 02
    Serial PEF or another objective asthma variability test
    Why
    Demonstrate variable expiratory airflow when asthma remains plausible.
    Interpretation and limitations
    Use the current NICE diagnostic sequence and record treatment exposure. Positive repeated variability supports asthma; an uninformative record or negative result on high-dose ICS does not automatically establish COPD.
  3. 03
    FeNO and blood eosinophil count
    Why
    Identify type 2 inflammatory traits relevant to asthma and ICS response.
    Interpretation and limitations
    Raised markers support eosinophilic inflammation but occur in phenotypes across diagnostic labels. Low values after corticosteroid, during smoking or outside an active period have limited exclusion value.
  4. 04
    Chest radiograph and selected inspiratory CT
    Why
    Identify emphysema, bronchiectasis, cancer, ILD or another structural cause.
    Interpretation and limitations
    Hyperinflation is supportive but not diagnostic of COPD. CT is not routine for every uncertain airway diagnosis; use it when symptoms, gas transfer, radiography or recurrent infection are discordant.

Differential diagnosis

01

Asthma alone

Clear symptom and airflow variability, atopy and little exposure burden favour asthma, even when obstruction is persistent after years of disease.

02

COPD alone

Progressive exertional symptoms, substantial harmful exposure, emphysema and persistently obstructed spirometry without convincing variability favour COPD.

03

Bronchiectasis

Daily purulent sputum, recurrent bacterial growth and bronchial dilatation on CT may explain obstruction and exacerbations better than overlap.

04

Inducible laryngeal obstruction

Inspiratory noise, throat tightness and abrupt exercise symptoms with normal expiratory testing suggest dynamic laryngeal closure.

05

Heart failure

Orthopnoea, oedema and cardiac congestion can mimic chronic airway symptoms and should not be assigned to overlap without objective pulmonary evidence.

Additional chapter-specific clues

Alternative disease signalRed flag

Clubbing, crackles, haemoptysis, inspiratory noise, orthopnoea, oedema, disproportionate hypoxaemia, systemic illness or restriction should move assessment beyond asthma and COPD rather than being forced into overlap.

Management

01ReconstructBuild an evidence timelineFirst stepThe record contains asthma, COPD, overlap or conflicting airway labels.+
  1. 1Retrieve age at symptom onset, childhood or allergic history, attacks, smoking and occupational exposure, prior objective tests and response to treatment.
  2. 2Check whether each historical diagnosis was based on acceptable spirometry, documented variability or only symptoms and a therapeutic trial.
  3. 3Repeat quality-assured spirometry when stable, documenting bronchodilator and corticosteroid exposure, then add asthma tests using the current NICE sequence if needed.
  4. 4AlternativeState separate conclusions: asthma evidence, COPD evidence, alternative disease evidence and what remains uncertain, rather than one unsupported overlap label.
02Asthma safetyProtect against asthma riskCurrent or historical evidence makes asthma clinically credible.

Complications

01

Frequent exacerbations

Combined variable inflammation and fixed physiological impairment may increase acute deteriorations, admissions and recovery time, creating an additional need for recognition and targeted treatment.

02

Accelerated functional decline

Continued exposure, repeated attacks and persistent obstruction can reduce exercise capacity and reserve more rapidly than symptoms alone suggest.

03

Respiratory failure

Advanced gas trapping, ventilation-perfusion mismatch and muscle fatigue can produce chronic or acute-on-chronic hypoxaemic and hypercapnic failure.

04

Inappropriate treatment burden

An imprecise label may drive excessive corticosteroid or bronchodilator escalation while adherence, exposure, infection or an alternative diagnosis remains unaddressed.

Monitoring and follow-up

  • Track asthma attacks, systemic corticosteroid courses, COPD exacerbations, admissions and antibiotic use separately because they may have different triggers and preventive strategies.
  • Review symptom timing, night waking, reliever use, MRC breathlessness, exercise tolerance and validated control scores rather than using one label-based outcome.
  • Repeat spirometry when a meaningful longitudinal change would alter management, ensuring test quality and treatment context are comparable.
  • At every inhaler review observe technique, reconcile duplicate ingredients, confirm actual collection and assess candidiasis, pneumonia, tremor, palpitations or antimuscarinic effects.
  • Monitor smoking status, vaccination, rehabilitation participation, weight, oxygenation and relevant cardiac or sleep comorbidity as actively as prescriptions.

Special situations

Reversibility is not a border

COPD may show bronchodilator response and long-standing asthma may remain obstructed. Repeated variability, history and inflammatory context carry more meaning than a single binary reversibility label.

Eosinophils cross labels

Blood eosinophilia can identify a corticosteroid-responsive trait in airway disease without proving asthma. Its meaning depends on attacks, smoking, recent steroids and the treatment question.

One patient needs two pathways

A patient with convincing asthma and smoking-related COPD needs asthma-safe ICS-containing treatment plus COPD rehabilitation, exposure care and bronchodilation; neither pathway cancels the other.

Device burden mimics resistance

Multiple different inhalers create technique errors and ingredient duplication. A simpler regimen that the person can actually use may outperform nominal pharmacological escalation.

Uncertainty can be honest

Documenting 'persistent obstruction with probable asthma traits; COPD contribution under evaluation' is safer than false certainty because it preserves treatment rationale and future reappraisal.

Common pitfalls

  1. 01

    Using smoking history to exclude asthma or atopy to exclude COPD.

  2. 02

    Equating any bronchodilator reversibility with asthma and any fixed obstruction with COPD.

  3. 03

    Prescribing LABA monotherapy or SABA-only treatment when credible asthma features are present.

  4. 04

    Using ICS alone for COPD symptoms while neglecting long-acting bronchodilation, smoking support and rehabilitation.

  5. 05

    Adding inhalers for discordant breathlessness without investigating heart failure, anaemia, obesity, ILO or deconditioning.

  6. 06

    Leaving 'asthma-COPD overlap' on the record without evidence, treatment rationale or a plan to revisit uncertainty.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
RespiratoryOriginal SBA

Persistent obstruction with asthma evidence

A 62-year-old smoker had objectively confirmed variable asthma in early adulthood and now has persistent post-bronchodilator obstruction. Which treatment principle is most appropriate?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Respiratory topics →
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG245 Asthma recommendationsObjective diagnosis, ICS-containing treatment and asthma monitoring.
  • NICE NG115 COPD recommendationsCOPD diagnosis, diagnostic uncertainty, inhaled therapy and non-pharmacological care.
  • NHS England Adult breathlessness pathwayStructured assessment of respiratory, cardiac and systemic breathlessness causes.
  • NHS England Spirometry commissioning standardsQuality-assured diagnostic spirometry principles.
  • MHRA SABA overuse safety reminderSafety rationale against SABA-only asthma treatment and overuse.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Treatment follows risk. With convincing asthma, withholding ICS and using LABA alone is unsafe. With COPD, indiscriminate ICS exposes some people to pneumonia and local or systemic effects without replacing long-acting bronchodilation, smoking support or rehabilitation. The clinician therefore chooses an ICS-containing asthma-safe platform where needed, adds COPD-directed bronchodilation and non-pharmacological care according to symptoms and attacks, then reviews measurable benefit and adverse effects.

Key points

  • Asthma and COPD can coexist, but 'overlap' has no single universally accepted diagnostic test and should not become a substitute for documenting each condition's evidence.
  • Asthma is characterised by variable symptoms and variable expiratory airflow limitation; COPD requires persistent post-bronchodilator airflow obstruction in the right exposure and clinical context.
  • A smoking history does not rule out asthma, and bronchodilator reversibility does not by itself rule out COPD; interpret magnitude, repetition, treatment and history together.
  • When credible asthma features are present, ensure an inhaled corticosteroid-containing regimen and avoid LABA monotherapy or SABA-only asthma treatment.
  • When COPD traits are present, address smoking, vaccination, pulmonary rehabilitation, breathlessness, exacerbations and long-acting bronchodilation rather than relying on inhaled corticosteroid alone.
  • Blood eosinophils and FeNO can support an inflammatory trait but are affected by corticosteroids and do not determine diagnosis in isolation.
  • Repeat quality-assured spirometry when the person is stable and treatment is documented; poor-quality or acute-illness spirometry creates false diagnostic certainty.
  • Discordance between symptoms and spirometry should trigger alternatives such as heart failure, obesity, deconditioning, bronchiectasis, small-airways disease, ILO, anaemia or pulmonary vascular disease.
  • 05
    Full pulmonary function including gas transfer and lung volumes
    Why
    Characterise hyperinflation, restriction and parenchymal or vascular impairment.
    Interpretation and limitations
    Reduced gas transfer with emphysema supports COPD, while normal transfer may fit asthma, but neither is absolute. Restriction or disproportionately low transfer should redirect the differential.
  • 06
    Full blood count, ECG, natriuretic peptide and targeted cardiac testing
    Why
    Find common non-airway causes of chronic breathlessness.
    Interpretation and limitations
    Select tests from age, symptoms and examination. Anaemia, arrhythmia and heart failure frequently coexist with airway disease and can explain poor response to escalating inhalers.
    • +
    1. 1Ensure treatment contains inhaled corticosteroid and do not prescribe LABA monotherapy or SABA as the only asthma medicine.
    2. 2Choose a licensed AIR, MART or other ICS-containing regimen under current NICE guidance, matching device to technique, inspiratory ability and preference.
    3. 3EscalationProvide an asthma action plan and address adherence, smoke, occupation, rhinitis and attacks; escalate urgent deterioration using the acute asthma pathway.
    4. 4If fixed obstruction and COPD symptom burden coexist, add COPD-directed long-acting bronchodilation and non-drug interventions without removing the asthma safety platform.
    03COPD traitsTreat persistent obstruction comprehensivelyPost-bronchodilator obstruction and exposure history support COPD-related disease.+
    1. 1Offer smoking or vaping cessation support, vaccination and self-management, assess exacerbations and breathlessness, and refer eligible people for pulmonary rehabilitation.
    2. 2Use long-acting bronchodilation according to symptoms, attacks, asthma features and current NICE COPD guidance, checking device technique and benefit.
    3. 3Use ICS only within an appropriate combination when indicated; review pneumonia, oral candidiasis and systemic corticosteroid risk rather than assuming more ICS is always better.
    4. 4Assess oxygenation, comorbidity, nutrition and function, and investigate disproportionate decline or infection for bronchiectasis, cancer, cardiac disease or another diagnosis.
    04Follow-upUse response as new evidenceA treatment plan has been started despite residual diagnostic uncertainty.+
    1. 1Define the intended outcome before changing therapy: attacks, night symptoms, breathlessness score, exercise capacity, reliever use or lung function.
    2. 2Review adherence and device delivery before interpreting failure; identify adverse effects and non-airway symptom drivers at the same visit.
    3. 3Retain treatments with meaningful benefit and appropriate indication, withdraw unnecessary components safely, and update the evidential diagnosis in the record.
    4. 4Refer to respiratory physiology or specialist airway care when discordance persists, rather than cycling through empirical inhalers indefinitely.
    Key medicines and prescribing safety4 treatments · regimens, roles and cautions+
    Provide an asthma-safe anti-inflammatory and bronchodilator foundation when asthma is credible.

    Inhaled corticosteroid-formoterol AIR or MART

    Use the exact licensed product, strength and as-needed or maintenance-and-reliever schedule selected under NICE and the local formulary.

    Confirm licence and maximum daily inhalations because products are not interchangeable. Review high use promptly; monitor candidiasis, dysphonia and systemic steroid exposure, and do not duplicate long-acting beta2 agonists.

    Improve bronchodilation in COPD traits and selected asthma pathways with persistent symptoms.

    Long-acting muscarinic antagonist add-on

    Give the locally formulary-approved inhaled once-daily or twice-daily product at its licensed device-specific adult dose after technique assessment.

    Dry mouth and urinary or ocular antimuscarinic effects can occur. Avoid powder or mist exposure to the eyes, assess glaucoma or urinary retention risk, and do not confuse maintenance LAMA with rapid rescue therapy.

    Provide dual long-acting bronchodilation for persistent COPD breathlessness or exacerbation risk.

    LABA-LAMA fixed-dose inhaler for COPD traits

    Use one licensed maintenance regimen from the local COPD formulary, with inhalation frequency determined by the selected device and product.

    Do not use LABA without ICS when asthma is credible. Check for duplicate LABA or LAMA ingredients, palpitations, tremor, urinary effects and technique; reassess benefit rather than accumulating devices.

    Relieve breakthrough bronchoconstriction while the long-term regimen addresses inflammation and fixed obstruction.

    Short-acting bronchodilator rescue treatment

    Use the prescribed inhaled dose as needed within a written plan and alongside inhaled corticosteroid whenever asthma is present.

    Rising use or shorter relief suggests deterioration and needs prompt assessment. SABA-only treatment is unsafe in asthma, while excessive beta2 agonist can cause tachycardia, tremor, hypokalaemia and lactic acidosis.

    Authoring stateComplete draft
    Clinical stateAwaiting review
    JurisdictionUnited Kingdom
  • Record the evidential basis and residual uncertainty in the notes so future clinicians know why ICS, bronchodilation or specialist testing was chosen.
  • Review the diagnosis longitudinally: age, exposure, variability, attacks, imaging and response accumulate more reliable evidence than one clinic snapshot.